Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs GeneDx Holdings Corp (WGS) Price & Performance

MicroSectors FANG and Innovation 3X Leveraged ETNTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

MicroSectors FANG and Innovation 3X Leveraged ETN vs GeneDx Holdings Corp — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $28.56, while GeneDx Holdings Corp trades at $62.69 (market cap $1.96B). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

FNGUWGS
Sector
Leveraged / InverseTechnology
52-Week High
$36.15$167.51
52-Week Low
$13.73$34.51
Market Cap
$1.96B
Enterprise Value
$1.96B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU, a leveraged ETN tracking the FANG+ Index, trades at $28.79, down 0.38% on the day. Technical indicators show mixed signals with moving averages bullish but oscillators bearish, including overbought RSI readings above 80. Recent performance highlights extreme volatility, with a documented 16% single-session drop on June 5, 2026, illustrating the amplified risks of its 3x leverage structure.

The outlook for FNGU is highly speculative, driven entirely by momentum in its underlying tech stocks rather than traditional fundamentals. Investment opportunity exists for aggressive traders betting on continued tech sector strength, but risks are severe, including decay from daily resets and catastrophic losses during market downturns, as recent news demonstrates.

GeneDx Holdings Corp

WGS trades at $62.73, up 0.48% on the day, amid a bearish technical signal and negative earnings momentum. The stock faces significant headwinds from a class action lawsuit alleging securities fraud tied to a 49% stock decline, while fundamentals show a net loss of $21.02 million in 2025 and deteriorating profitability into 2026. Analyst consensus remains bullish with a $75.40 price target, but recent news flow is overwhelmingly negative.

The outlook is clouded by legal risks and weak financial performance, though analyst optimism suggests potential recovery if the company can stabilize operations. Key risks include litigation outcomes, execution on profitability, and market sentiment shifts. The stock's trajectory hinges on resolving legal challenges and demonstrating sustainable earnings improvement.

Returns comparison

Trailing returns across standard periods

About MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.

Read more on FNGU

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS